Showing results (261-270 of 333) with videos related to
Sort By:
Pageof 34
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 MutationsAlessandra Bearz, Jean-François Martini, Jacek Jassem, et al.Clinical Lung Cancer|June 21, 2023
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II TrialKimio Yonesaka, Hidetoshi Hayashi, Atsushi Nakamura, et al.The Oncologist|November 25, 2022
Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)Hiromichi Matsuoka, Junji Tsurutani, Yasutaka Chiba, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2021
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)Hirohito Tada, Tetsuya Mitsudomi, Toshihiro Misumi, et al.JTO Clinical and Research Reports|August 9, 2022
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLCHiroaki Kanemura, Hidetoshi Hayashi, Shuta Tomida, et al.JAMA Oncology|October 15, 2020
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical TrialHidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami, et al.Frontiers in Immunology|December 27, 2023
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective studyTakashi Kurosaki, Kenji Chamoto, Shinichiro Suzuki, et al.Cancer|February 2, 2016
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trialMasayuki Takeda, Takeharu Yamanaka, Takashi Seto, et al.Lung Cancer (Amsterdam, Netherlands)|April 20, 2025
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)Yoshimasa Shiraishi, Takayuki Shimose, Kazunori Tobino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2019
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L)Takashi Seto, Koichi Azuma, Takeharu Yamanaka, et al.Pageof 34